Lenvatinib: beside an established treatment under test
55 studies: an approved drug, surgery or radiation is what the study tests. Page 1 of 1. Open to participants first (32), then studies with results posted, then the rest; newest registration first within each.
- Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer PatientsRecruitingNCT07928167Phase 2Report a problem
- Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney CancerNot yet recruitingNCT07922928Phase 2Report a problem
- Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT07832006Phase 2Report a problem
- Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver CancerNot yet recruitingNCT07829926Phase 2Report a problem
- Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver CancerNot yet recruitingNCT07537946Phase 3Report a problem
- Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07408804Not applicableReport a problem
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingNCT07405164Phase 3Report a problem
- An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.RecruitingNCT07282262Phase 2Report a problem
- A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECISTNot yet recruitingNCT07208526Not applicableReport a problem
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCRecruitingNCT07157969Phase 2Report a problem
- Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingNCT07047586Phase 2Report a problem
- Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCCRecruitingNCT06904196Phase 2Report a problem
- Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTTRecruitingNCT06904183Phase 2Report a problem
- Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.RecruitingNCT06903312Phase 4Report a problem
- Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCCRecruitingNCT06841172Phase 3Report a problem
- Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)RecruitingNCT06726421Phase 3Report a problem
- Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular CarcinomaNot yet recruitingNCT06708650Not applicableReport a problem
- TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTTRecruitingNCT06622031Not applicableReport a problem
- The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular CarcinomaRecruitingNCT06609850Not applicableReport a problem
- Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic TreatmentNot yet recruitingNCT06592612Phase 2Report a problem
- Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon CancersRecruitingNCT06580574Phase 2Report a problem
- Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular CarcinomaRecruitingNCT06550921Not applicableReport a problem
- Lenvatinib Plus DEB-TACE and HAIC Vs. Lenvatinib Plus DEB-TACE for Large HCC with PVTTRecruitingNCT06492395Phase 3Report a problem
- Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor ThrombosisRecruitingNCT06389422Phase 2Report a problem
- Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.RecruitingNCT06311942Phase 4Report a problem
- FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind TrialRecruitingNCT06201065Phase 3Report a problem
- Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCCRecruitingNCT05842317Phase 1/2Report a problem
- SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)Not yet recruitingNCT05718232Phase 3Report a problem
- Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCCRecruitingNCT05608213Phase 3Report a problem
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingNCT05327686Phase 2Report a problem
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerRecruitingNCT05168163Phase 2Report a problem
- TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTTRecruitingNCT04967495Not applicableReport a problem
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Phase 3Results postedReport a problem
- HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICCCompletedNCT07304388Phase 2Report a problem
- Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCCCompletedNCT07184424Not applicableReport a problem
- Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor ThrombosisCompletedNCT06233981Phase 2Report a problem
- Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTTWithdrawnNCT05592197Not applicableReport a problem
- HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCCStatus unknownNCT05582278Phase 2Report a problem
- Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)WithdrawnNCT05487859Phase 2Report a problem
- IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver TransplantationStatus unknownNCT05339581Not applicableReport a problem
- HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTTCompletedNCT05166239Phase 2Report a problem
- A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)Active, not recruitingNCT05030506Phase 1Report a problem
- Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCCStatus unknownNCT05007587Early Phase 1Report a problem
- Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)Active, not recruitingNCT04976634Phase 2Report a problem
- A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Phase 3Report a problem
- Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 TrialStatus unknownNCT04687163Phase 3Report a problem
- Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaCompletedNCT04642547Not applicableReport a problem
- To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.Status unknownNCT04443049Not applicableReport a problem
- The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04053985Phase 3Report a problem
- Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus InfectionWithdrawnNCT04044651Phase 2/3Report a problem
- TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCCStatus unknownNCT03905967Phase 3Report a problem
- Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaStatus unknownNCT03838796Not applicableReport a problem
- HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCCWithdrawnNCT03803254Phase 2Report a problem
- Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCCWithdrawnNCT03744247Phase 3Report a problem
- UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib AloneSuspendedNCT03139747Phase 2Report a problem